Otezla 30 MG tablet 60S
Ended Awarded
- Contract number
- SPE2DB25FAVLE
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $19,399
Award facts
- Contract value 100% obligated
- $19,399.14 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
This delivery order awards DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, a firm fixed-price contract valued at $19,399.14 for the supply of Otezla 30 mg tablets (60-count units) with an ultimate completion date of June 2, 2025. The contract was awarded without a set-aside designation on May 30, 2025, by the Defense Logistics Agency (DLA), a component of the Department of Defense responsible for supply chain management across military and federal healthcare systems. Performance will be executed from the vendor's location in Conshohocken, Pennsylvania.
This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA valued at $499,999,999 and valid through November 2026, which authorizes the issuance of firm fixed-price delivery orders for a comprehensive range of pharmaceutical products supporting medical supply needs at military health facilities worldwide. The underlying IDC, established under the SPE2DB program, covers an extensive portfolio including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables. Otezla, an oral immunosuppressant commonly prescribed for psoriasis, psoriatic arthritis, and Behçet's disease, represents one product category within this broad pharmaceutical supply agreement supporting Department of Defense healthcare operations.
Quick answers
Who was awarded contract SPE2DB25FAVLE?
SPE2DB25FAVLE was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on May 30, 2025.
How much is contract SPE2DB25FAVLE worth?
The government has obligated $19,399 on SPE2DB25FAVLE.
Is contract SPE2DB25FAVLE an order under another contract?
Yes. SPE2DB25FAVLE is a delivery order under SPE2DB24D2106, an indefinite delivery contract.
Was contract SPE2DB25FAVLE competed?
The extent of competition for SPE2DB25FAVLE was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award